A production method for pluripotent stem cells is provided, the method including the following (a) and (b): (a) a process filling a culture container with a liquid medium and thereafter raising, the temperature of the liquid medium in the culture container to the temperature at which pluripotent stem cells can proliferate; and (b) a process seeding pluripotent stem cells in the liquid medium in the culture container and culturing the pluripotent stem cells in suspension.

Provided is a new type serum-free medium. The medium comprises: DMEM with high glucose (the content of glucose being 4.5 g/L), B27, recombinant human basic fibrolast growth factor (b-FGF), nicotinamide, N-2, vinblastine III (conophylline), non-essential amino acid (NEAA), heparin, epidermal growth factor (EGF), hepatocyte growth factor (HGF), a serum replacement (SR), an insulin-transferrin-selenium complex (ITS), and pentagastrin. Inducing differentiation of mesenchymal stem cells into insulin-secretion-like cells can be achieved in six days in one step using the medium.

Provided herein are methods and compositions for producing cannabinoids and other metabolites in a host cell.

Delivering a payload across a plasma membrane of a cell includes providing a population of cells and contacting the population of cells with a volume of an aqueous solution. The aqueous solution includes the payload and alcohol content greater than 5 percent concentration. The volume of the aqueous solution may be a function of exposed surface area of the population of cells, or may be a function of a number of cells in the population of cells. Related compositions, apparatus, systems, techniques, and articles are also described.

The present disclosure provides a cell system comprising eukaryotic cells in a hydrogel comprising nanofibrillar cellulose in cell storage medium at a temperature in the range of 0-25° C. The present disclosure also provides a method for storing eukaryotic cells, the method comprising providing eukaryotic cells, providing nanofibrillar cellulose, combining the cells and the nanofibrillar cellulose to form the cell system, and storing the cell system at a temperature in the range of 0-25° C.

Liver metabolism studies are limited by the inability to expand primary hepatocytes in vitro while maintaining their metabolic functions. Human hepatic three dimensional organoids have been established for use in these studies, but hepatic organoids from adult donors had impaired expansion. Methods of achieving expansion of adult donor-derived hepatic organoids (HepAOs) and HepG2 cells (HepGOs) from single cells in organoid cultures using combinations of growth factors and small molecules are described, with assessment of expansion dynamics, gluconeogenic and HNF4α expression, and albumin secretion. The invention discloses conditions including limiting A8301 and incorporating FSK and OSM to allow the expansion of HepAOs from adult donors and HepGOs with gluconeogenic competence. These models increase the repertoire of human hepatic cellular tools available for use in liver metabolic assays.

The present invention aims to provide a novel compound capable of promoting cell proliferation in a cell culture (particularly three-dimensional cell culture). The hydrazide compound represented by the formula (I);

##STR00001##

wherein each symbol is as defined in DESCRIPTION, or a salt thereof, and a composition containing same can remarkably promote cell proliferation, sphere formation, cyst formation and/or organoid formation, and can also remarkably inhibit the activities of kinase such as LATS1, LATS2 and the like.

Methods of ex-vivo culture of gammadelta T-cells and gammadelta T-cell enriched cell populations are provided and, more particularly, methods for enhancing functionality of gammadelta T-cell populations by treating the cells with a nicotinamide in combination with cytokines enhancing gammadelta T-cell homing and/or retention potential. Also envisioned are compositions comprising cultured gammadelta T-cells and mixed gammadelta T-cell enriched cell populations and therapeutic uses thereof.

Provided is a method of producing an osteoblast construct from iPS cells, the method including the steps of: (1) inducing formation of an embryoid body by subjecting undifferentiated iPS cells to non-adherent culture; (2) inducing differentiation of the iPS cells into mesodermal cells by subjecting the embryoid body of the iPS cells obtained in the step (1) to non-adherent culture; and (3) inducing differentiation into osteoblasts by subjecting the mesodermal cells of the iPS cells obtained in the step (2) to non-adherent culture, wherein the steps (1) and (2) are each performed using a culture vessel comprising a bottom surface and a circular side wall arranged upright on the bottom surface, the bottom surface having a plurality of depressed portions arranged independently of each other.

Disclosed is a L-isoleucine-producing Corynebacterium glutamicum fermentation medium, comprising a basal medium and a growth factor, wherein the growth factor consists of choline, betaine and vitamin B6, and the contents of each ingredient in the fermentation medium are: 0.2-1 g/L choline, 0.25-0.5 mg/L betaine, and 0.05-0.3 mg/L vitamin B6. Also disclosed is a method for cultivating the L-isoleucine-producing Corynebacterium glutamicum, comprising: inoculating the L-isoleucine-producing Corynebacterium glutamicum onto the fermentation medium, wherein the volume of the bacteria liquid accounts for 5-20% of the volume of the fermentation medium, adjusting the pH to 6.5-7 with aqueous ammonia, controlling the dissolved oxygen to 30-50%, and fermenting for 25-30 h; then decreasing the dissolved oxygen to 15-25%, and feeding a 50-80% glucose solution into the fermentation broth to control the residual sugar at 3-4%, continuing the fermentation until 60-70 hours, then terminating the fermentation, and controlling the temperature of the overall fermentation process at 29-33° C.